| Literature DB >> 32502457 |
Jason Fangusaro1, Olaf Witt2, Pablo Hernáiz Driever3, Asim K Bag4, Peter de Blank5, Nadja Kadom6, Lindsay Kilburn7, Robert M Lober8, Nathan J Robison9, Michael J Fisher10, Roger J Packer11, Tina Young Poussaint12, Ludmila Papusha13, Shivaram Avula14, Alba A Brandes15, Eric Bouffet16, Daniel Bowers17, Anton Artemov13, Murali Chintagumpala18, David Zurakowski19, Martin van den Bent20, Brigitte Bison21, Kristen W Yeom22, Walter Taal23, Katherine E Warren24.
Abstract
Paediatric low-grade gliomas (also known as pLGG) are the most common type of CNS tumours in children. In general, paediatric low-grade gliomas show clinical and biological features that are distinct from adult low-grade gliomas, and the developing paediatric brain is more susceptible to toxic late effects of the tumour and its treatment. Therefore, response assessment in children requires additional considerations compared with the adult Response Assessment in Neuro-Oncology criteria. There are no standardised response criteria in paediatric clinical trials, which makes it more difficult to compare responses across studies. The Response Assessment in Pediatric Neuro-Oncology working group, consisting of an international panel of paediatric and adult neuro-oncologists, clinicians, radiologists, radiation oncologists, and neurosurgeons, was established to address issues and unique challenges in assessing response in children with CNS tumours. We established a subcommittee to develop consensus recommendations for response assessment in paediatric low-grade gliomas. Final recommendations were based on literature review, current practice, and expert opinion of working group members. Consensus recommendations include imaging response assessments, with additional guidelines for visual functional outcomes in patients with optic pathway tumours. As with previous consensus recommendations, these recommendations will need to be validated in prospective clinical trials.Entities:
Year: 2020 PMID: 32502457 DOI: 10.1016/S1470-2045(20)30064-4
Source DB: PubMed Journal: Lancet Oncol ISSN: 1470-2045 Impact factor: 41.316